Overview

Ssafety and Tolerability of PRO-185

Status:
Not yet recruiting

Trial end date:
2022-08-31

Target enrollment:

Participant gender:

Summary

Phase I Study to evaluate safety and tolerability of PRO-185 (naphazoline/hypromellose) ophthalmic solution through evaluation of vital signs, ocular signs such as intraocular pressure, hyperemia and mydriasis and adverse events.

Phase:

Phase 1

Details

Lead Sponsor:

Laboratorios Sophia S.A de C.V.

Treatments:

Naphazoline